Eli Lilly and Company (LLY)の価格はいくらですか

Eli Lilly and Company (LLY)の価格は$1,133.97です

Eli Lilly and Company (LLY)の時価総額は何ですか

Eli Lilly and Company (LLY)の時価総額は$1.068Tです

Eli Lilly and Company（LLY）PBR（株価純資産倍率）

Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.

年	P/B比率	変化
2026 (TTM)	29.97	-100.00%
2025	0.00	-100.00%
2024	48.99	0.66%
2023	48.67	49.11%
2022	32.64	11.26%
2021	29.34	2.47%
2020	28.63	-40.70%
2019	48.27	298.96%
2018	12.10	57.86%
2017	7.67	32.61%
2016	5.78	-9.56%
2015	6.39	28.23%
2014	4.98	54.29%
2013	3.23	-15.65%
2012	3.83	12.02%
2011	3.42	9.59%
2010	3.12	-24.25%
2009	4.12	-37.07%
2008	6.54	51.79%
2007	4.31	-16.39%
2006	5.16	-9.59%
2005	5.70	1.26%
2004	5.63	-27.31%
2003	7.75	-6.41%
2002	8.28	-30.49%
2001	11.91	-28.36%
2000	16.63	0.00%

年

P/B比率

変化

2026 (TTM)

29.97

-100.00%

2025

0.00

-100.00%

2024

48.99

0.66%

2023

48.67

49.11%

2022

32.64

11.26%

2021

29.34

2.47%

2020

28.63

-40.70%

2019

48.27

298.96%

2018

12.10

57.86%

2017

7.67

32.61%

2016

5.78

-9.56%

2015

6.39

28.23%

2014

4.98

54.29%

2013

3.23

-15.65%

2012

3.83

12.02%

2011

3.42

9.59%

2010

3.12

-24.25%

2009

4.12

-37.07%

2008

6.54

51.79%

2007

4.31

-16.39%

2006

5.16

-9.59%

2005

5.70

1.26%

2004

5.63

-27.31%

2003

7.75

-6.41%

2002

8.28

-30.49%

2001

11.91

-28.36%

2000

16.63

0.00%

企業	P/B比率	P/B比率の差	国
Johnson & Johnson JNJ.US	7.6479	-74.48%	US
AbbVie Inc. ABBV.US	-78.0908	-360.57%	US
Roche Holding AG RO.SW	8.4776	-71.71%	CH
Merck & Co., Inc. MRK.US	8.5385	-71.51%	US
Novartis AG NOVN.SW	6.754	-77.46%	CH

企業

P/B比率

P/B比率の差

国